FBLG FibroBiologics Inc

FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Pete O’Heeron, Chief Executive Officer of FibroBiologics, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16, 2024 at 10:00 a.m. ET.

For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com. 

About FibroBiologics 

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com. 

General Inquiries: info@fibrobiologics.com 

Investor Relations: Nic Johnson Russo Partners (212) 845-4242 fibrobiologicsIR@russopr.com 

Media Contact: Liz Phillips Russo Partners (347) 956-7697 Elizabeth.phillips@russopartnersllc.com